Department of Neurology, Hanyang University College of Medicine, Seoul, Korea
Rituximab is a chimeric mouse human anti-CD20 monoclonal antibody that can reduce B cell numbers and antibody levels and has been prescribed for refractory neuromyelitis optica spectrum disorder (NMOSD). We report a case of delayed hepatitis B reactivation after repeated rituximab treatments with antibodies against aquaporin-4 in a seropositive NMOSD patient with chronic hepatitis B infection.
Journal of Multiple Sclerosis and Neuroimmunology 12(2):35-38, 2021
